Products IMU-838 tablets + Placebo matching IMU-838 tablets
IMU-838 tablets + Placebo matching IMU-838 tablets Phase 3 Active 📈 Rising Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Relapsing-Remitting
Jan 12, 2022 → Oct 1, 2033
About IMU-838 tablets + Placebo matching IMU-838 tablets IMU-838 tablets + Placebo matching IMU-838 tablets is a phase 3 stage product being developed by Immunic for Multiple Sclerosis, Relapsing-Remitting. The current trial status is active. This product is registered under clinical trial identifier NCT05201638. Target conditions include Multiple Sclerosis, Relapsing-Remitting.
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT05201638 Phase 3 Active Jan 12, 2022 Oct 1, 2033 Multiple Sclerosis, Relapsing-Remitting NCT05134441 Phase 3 Active Nov 18, 2021 Sep 1, 2033 Multiple Sclerosis
Competing Products 20 competing products in Multiple Sclerosis, Relapsing-Remitting
See all competitors Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1
Other Products from Immunic